Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden

Francis Couturaud; Clive Kearon; Christophe Leroyer; Bernard Mercier; Jean Francois Abgrall; Grégoire Le Gal; Karine Lacut; Emmanuel Oger; Luc Bressollette; Claude Ferec; Michel Lamure; Dominique Mottier; for the Groupe d’Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O)

doi:10.1160/TH06-06-0328

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2006; 96(06): 744-749
DOI: 10.1160/TH06-06-0328

Blood Coagulation, Fibrinolysis and Cellular Haemostasis

Schattauer GmbH

Incidence of venous thromboembolism in first-degree relatives of patients with venous thromboembolism who have factor V Leiden

Authors

Francis Couturaud

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Clive Kearon

⁴McMaster University and the Henderson Research Centre, Hamilton, Ontario, Canada
Christophe Leroyer

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Bernard Mercier

²Transfusion Centre, Brest, France
Jean Francois Abgrall

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Grégoire Le Gal

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Karine Lacut

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Emmanuel Oger

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Luc Bressollette

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Claude Ferec

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France
Michel Lamure

³Statistical Department, Lyon, France
Dominique Mottier

¹G.E.T.B.O. (Groupe d’Etude de la Thrombose de Bretagne Occidentale), EA 3878, Department of Internal Medicine and Chest Diseases, Brest, France

for the Groupe d’Etude de la Thrombose de Bretagne Occidentale (G.E.T.B.O)

Abstract

Summary

The factor V Leiden (FVL) mutation, a genetic abnormality with an autosomal mode of inheritance, is associated with an increased risk of venous thromboembolism (VTE). We aimed to determine the annual incidence of VTE in first-degree relatives of patients with VTE and FVL and to identify factors in patients and the relatives that influence this incidence. In this retrospective and prospective cohort study, the incidence of objectively diagnosed first episodes of VTE was assessed in 553 first-degree relatives of 161 patients with acute VTE and FVL. The annual incidence of VTE was 0.43% (95% CI, 0.3 to 0.56) with FVL and 0.17 % (95% CI, 0.07 to 0.27) without FVL (relative risk of 2.5, 95% CI, 1.3 to 4.7). A majority (70%) of episodes of VTE were provoked, and this proportion was similar with and without FVL. A larger proportion of VTE was provoked in women (83%) that in men (33%), with the difference accounted for by pregnancy and use of oral contraceptives. The proportion of pregnancies complicated by VTE was 3.9% (95% CI, 2.0–5.8) with FVL and 1.4% (95% CI, 0.04–2.7) without FVL. FVL is associated with a two-to threefold increase in VTE in first-degree relatives of patients with VTE. No subgroup of relatives was identified who require more than routine prophylaxis because of a particularly high risk of VTE.

Keywords

Familial thrombosis - venous thrombosis - factor V Leiden

Full Text

References

References
1 Koster T, Rosendaal FR, de Ronde H. et al. Venous thrombosis due to poor anticoagulant response to activated proteinC: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
2 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
3 Ridker PM, Miletich JP, Stampfer MJ. et al. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-2.
4 Simioni P, Prandoni P, Lensing AWA. et al. The risk of recurrent venous thromboembolism in patients with an Arg506>Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
5 Eichinger S, Pabinger I, Stümpflen A. et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-8.
6 Lindmarker P, Schulman S, Sten-Linder M. et al. and the DURAC Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-9.
7 Kearon C, Gent M, Hirsh J. et al. l. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-7.
8 Ridker PM, Goldhaber SZ, Danielson E. et al. PREVENT investigators. Long term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
9 Kearon C, Ginsberg JS, Kovacs MJ. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent thromboembolism. N Engl J Med 2003; 349: 631-9.
10 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia. Arch Intern Med 2006; 166: 729-36.
11 Rosendaal FR, Koster T, Vandenbroucke JP. et al. High risk of thrombosis in patients with homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-8.
12 Ridker PM, Hennekens CH, Lindpaintner K. et al. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
13 Leroyer C, Mercier B, Escoffe M. et al. Factor V leiden prevalence in venous thromboembolism patients. Chest 1997; 111: 1603-6.
14 Middeldorp S, Henkens CMA, Koopman MMW. et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20.
15 Simioni P, Sanson BJ, Prandoni P. et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
16 Lensen RPM, Betina RM, de Ronde H. et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 817-21.
17 Middeldorp S, Meinardi JR, Koopman MMW. et al. A prospective study of asymptomatic carriers of the factor V Leiden mutation to determine the incidence of venous thromboembolism. Ann Intern Med 2001; 135: 322-7.
18 Simioni P, Tormene PPrandoni. et al. Incidence of venous thromboembolism in asymptomatic family members who are carriers of factor V Leiden: a prospective cohort study. Blood 2002; 99: 1938-42.
19 Vossen CY, Conard J, Fontcuberta J. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 03: 459-64.
20 Hull RD, Hirsh J, Carter CJ. et al. Pulmonary angiography, ventilation lung scanning and venography for clinically suspected pulmonary embolism with abnormal pulmonary perfusion lung scan. Ann Intern Med 1983; 98: 891-9.
21 Kearon C, Julian J, Newman TE. et al. Non invasive diagnosis of deep venous thrombosis. Ann Intern Med 1998; 128: 663-77.
22 The PIOPED investigators. Value of the ventilation perfusion lung scan in acute pulmonary embolism. J Am Med Assoc 1990; 263: 2753.
23 Heit JA, Silverstein MD, Mohr DN. et al. Risks factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-15.
24 Lapostolle F, Surget V, Borron S. et al. Severe pulmonary embolism associated with air travel. N Engl J Med 2001; 345: 779-83.
25 Bloom JW, Vanderschoot JPM, Oostindiër MJ. et al. Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results ofa record linkage study. J Thromb Haemost 2006; 04: 529-35.
26 Oger E, Lacut K, Le Gal G. et al. Is APC resistance a risk factor for venous thromboembolism in patients over 70 years?. Thromb Haemost 2002; 88: 587-91.
27 Oger E. for the EPI-GETBO Study Group. Incidence of venous thromboembolism: a communitybased study in Western France. Thromb Haemost 2000; 83: 657-60.
28 Heit JA, Silvestein MD, Mohr DN. et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001; 86: 452-63.
29 Anderson Jr FA, Wheeler HB, Goldberg RJ. et al. A population based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester deep vein thrombosis Study. Arch Intern Med 1991; 151: 933-8.
30 Ridker PM, Glynn RJ, Miletich JP. et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997; 126: 528-31.